Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

References:

  1. Miller et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Abstract LBA1, European Society of Medical Oncology (ESMO) Congress, Milan, October 2010.
  2. Miller et al. Phase IIb/III trial of afatinib (BIBW 2992) + best supportive care (BSC) vs. placebo + BSC in patients failing 1–2 lines of chemotherapy and erlotinib/gefitinib (LUX-Lung 1).  Oral presentation, European Society of Medical Oncology (ESMO) Congress, Milan, October 2010.
  3. Yang et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lu
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CHESTERBROOK, Pa., Oct. 30, 2014   Auxilium ... a fully integrated specialty biopharmaceutical company, today announced ... 30, 2014. The Company highlighted important corporate, commercial, ... "We are very pleased with ... core growth products in our portfolio this quarter, ...
(Date:10/30/2014)... 2014 , Extensively hydrolyzed milk ...   Cow milk protein allergy (CMPA) is the leading cause ... now, it has been managed by eliminating milk proteins ... that it is possible to help build of oral ... children during the first year of life by using ...
(Date:10/30/2014)... 2014 nebulizer is a medical device used ... cystic fibrosis) that converts liquid medication into mist or ... lungs of a patient when inhaled through the mouth ... dominated by various devices powered by electric current and ... COPD and cystic fibrosis and growing number of geriatric ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 12, 2007 /PRNewswire-FirstCall/ --,InB:Biotechnologies, Inc. ("BioTech"), a ... announced strong positive,results in studies of vaccines ... novel, proprietary AIPwLV(TM) vaccine technology. The,studies were ... Molecular,Biotechnology (CMB), the Contract Research Organization led ...
... LUND, Sweden, March 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) ... a first human micro-dosing trial of an,I-3D ... was to determine the pharmacokinetic,characteristics of the ... healthy volunteers. , The study demonstrated that ...
Cached Medicine Technology:Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... 30, 2014 PreDiabetes Centers , ... Store shoppers with a supply of sugardown®, a ... reduce post-meal blood sugar spikes. Learning how to control ... important part of a diabetes prevention plan. , Shoppers ... one complimentary tube of sugardown. The offer expires November ...
(Date:10/30/2014)... Tara Haelle HealthDay Reporter ... More than 100 genes have been identified that appear ... And researchers say they are on their way ... contribute to the disorder. Autism spectrum disorders include ... social difficulties and repetitive behaviors. An estimated one in ...
(Date:10/30/2014)... 30, 2014 Horse Sense & ... riding to special needs individuals in the Jacksonville area, ... November 15 from 10-2:00 p.m. at Bailey's Farm (2202 ... to the public and is designed to raise awareness ... to the HSS Round-Up is free. Ticket purchases will ...
(Date:10/30/2014)... Hill, South Carolina (PRWEB) October 30, 2014 ... muscle, and should be more vigorously exercised to help ... He recently authored the book ‘Dementia Express: Lose Your ... The book uses counterintuitive reasoning and sometimes conflicting attitudes ... obstacle course for the mind, a reader must decipher ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... April 24 International SOS has launched a new ... flu outbreak to members of the public and the ... t ionalsos.com , provides updates on the ... that those in California, Texas and Mexico, or traveling ...
... from a telemedicine device company to that of a Telemedicine Encounter ... ... (PRWEB) April 24, 2009 -- AMD Global Telemedicine, Inc., announces the ... AMD will showcase its new end to end clinical telemedicine ...
... in real time during transportSCOTTSDALE, Ariz., April 24 ... GlobalMedia, an innovator of video imaging and visual ... announced today that it will unveil the newest ... the American Telemedicine Association (ATA) Annual Meeting and ...
... DETROIT, April 24, United American Healthcare Corporation (Nasdaq: ... management services to a managed care organization in Tennessee, ... the third fiscal quarter ended March 31, 2009 on ... Company will host a conference call at 4:30 p.m. ...
... intensity-modulated radiotherapy (IMRT), RapidArc(TM) radiotherapy, and stereotactic ... Varian Medical Systems (NYSE: ... spectrum of prostate cancer treatment technologies at ... at McCormick Place in Chicago from April ...
... dying, researchers report , , FRIDAY, April 24 (HealthDay News) ... fibrillation after heart bypass surgery are at increased long-term ... report sounds a warning bell for doctors about an ... concern, said Giovanni Filardo, director of the department of ...
Cached Medicine News:Health News:International SOS Releases Web Site to Educate Public About Swine Flu Outbreak 2Health News:AMD Global Telemedicine Inc. to Unveil New Solutions at ATA 2009 Conference in Las Vegas 2Health News:GlobalMedia Launches Telemedicine Product for Ambulatory and Emergency Care 2Health News:GlobalMedia Launches Telemedicine Product for Ambulatory and Emergency Care 3Health News:GlobalMedia Launches Telemedicine Product for Ambulatory and Emergency Care 4Health News:United American Healthcare Corporation to Host Fiscal 2009 Third Quarter Results Conference Call May 7th 2Health News:Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago 2Health News:Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago 3Health News:Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago 4Health News:Abnormal Heartbeat After Bypass a Bad Sign 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: